|Bid||12.54 x 100000|
|Ask||12.73 x 100000|
|Day's Range||12.55 - 12.55|
|52 Week Range||11.60 - 15.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced Japan's Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company's New Drug Application (NDA), which was submitted in March. If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in Japan for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the European Commission (EC) has approved an additional indication for the oral once-daily therapy XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). Men diagnosed with mHSPC tend to have a poor prognosis, with a median survival of approximately 3-4 years,1 underscoring the need for new treatment options.
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associated with muscle weakness. Astellas had extended the research pact initially set to expire on December 31 last year, through March of this year. But last week, Astellas gave written notice that it wants out of the pact altogether and gives up “all licenses and other rights” granted through the pact. In 2013, Astellas had initially signed up to get exclusive rights to co-develop and sell skeletal sarcomere activators in all indications. In turn, Cytokinetics had the right to co-promote and do some sales work in the U.S., Canada, and Europe. Should these drugs have been taken forward solely by Astellas, Cytokinetics could have received over $450 million in pre-commercialization and commercialization milestones plus royalties. No reason was given for the breakup, which will be official this November 1, nor updates on the programs. Cytokinetics is set to release its financials later this week. It comes two years after Cytokinetics’ reldesemtiv missed the primary endpoint in phase 2 amyotrophic lateral sclerosis trial. The Astellas-partnered drug failed to beat placebo on a lung function test in May 2019. It also comes a few months after Amgen Inc (NASDAQ: AMGN) culled its pact with Cytokinetics for heart failure omecamtiv mecarbil after unimpressive Phase 3 data. Price Action: CYTK shares are up 1.65% at $25.86, and ALPMY shares are up 0.98% at $15.14 during market trading hours on the last check Monday. See more from BenzingaClick here for options trades from BenzingaBristol-Myers Misses Q1 Profit As Pandemic Hits Cancer Drugs SalesAmgen Shares Drop On Light First Quarter Earnings Hit By Lower Prices© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.